Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 211-492-3 | CAS number: 652-67-5
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Except data obtained from the scientific literature, the studies performed either on Isosorbide (LAB 3085) or on LAB 3822 were performed according OECD good laboratory practices.
Cross-reference
- Reason / purpose for cross-reference:
- reference to other study
Data source
Reference
- Reference Type:
- other: analysis by an expert
- Title:
- Analysis of pharmacokinetics available data for Isosorbide risk assessment
- Author:
- Pf MARZIN D.
- Year:
- 2 010
- Report date:
- 2010
Materials and methods
Results and discussion
Applicant's summary and conclusion
- Conclusions:
- One application of isosorbide is the production of LAB 3822.
LAB 3822 contains then about 29 % of Isosorbide.
After administration, the LAB 3822 is hydrolysed by the pancreatic lipase. This hydrolysis split LAB 3822 into ISOSORBIDE and free fatty acids.
LAB 3822 is totally and rapidly transformed into isosorbide. Under these conditions, some of the toxicological studies were performed on LAB 3822 and data were extrapolated to isosorbide.
After administration of LAB 3822 (derivative of Isosorbide) animals are exposed to Isosorbide. The level of exposure is proportional to the dose. Exposure to isosorbide is higher when administered alone than when it is administered as LAB 3822, but the isosorbide dose equivalent administered at the maximum dose of LAB 3822 (0.67 g/kg) is largely lower that when it was administered alone (2g/kg). The T1/2 (plasma and urine) and Tmax (plasma) of isosorbide was not different when isosorbide is administered as LAB 3822 or as Isosorbide itself. In both cases males are more exposed than females. The excretion of isosorbide is almost in the urine as unchanged isosorbide.
The available data are sufficient to conclude that no pharmacokinetic study is needed for risk assessment.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
